P28 Antimicrobial activity of imipenem/relebactam and comparators against clinical Gram-negative bacilli collected in the UK: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2020–24
M Wise, M Allen, F Siddiqui, K Young, M Motyl, D Sahm · 2026
Read P28 Antimicrobial activity of imipenem/relebactam and comparators against clinical Gram-negative bacilli collected in the UK: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2020–24 by M Wise, M Allen, F Siddiqui, K Young, M Motyl, D Sahm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13305627.txt.
Description
M Wise, M Allen, and co-authors report, in a 2026 survey abstract, how well a carbapenem combo drug performs against resistant Gram-negative bacteria collected across the United Kingdom. Imipenem paired with relebactam, which blocks two beta-lactamase classes, was tested against more than four thousand clinical isolates gathered between 2020 and 2024 under a global monitoring program.
Over ninety-nine percent of the main enteric group could be killed by the drug, including every isolate carrying the KPC resistance enzyme. Against Pseudomonas aeruginosa, the success rate reached about ninety-six percent overall. The pairing kept working against most strains resistant to standard beta-lactams and against roughly seven in ten multi-drug Pseudomonas strains, edging out a rival pairing. The authors conclude it offers an important option for difficult UK hospital infections.
Catalog record
| CREATOR | M Wise, M Allen, F Siddiqui, K Young, M Motyl, D Sahm |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |